

# ISO 12417-1:2024-02 (E)

## Cardiovascular implants and extracorporeal systems - Vascular device-drug combination products - Part 1: General requirements

---

<b>Contents</b>		<b>Page</b>
Foreword .....		v
Introduction .....		vi
<b>1</b>	<b>Scope .....</b>	<b>1</b>
<b>2</b>	<b>Normative references .....</b>	<b>2</b>
<b>3</b>	<b>Terms and definitions .....</b>	<b>2</b>
<b>4</b>	<b>Intended performance .....</b>	<b>6</b>
4.1	General .....	6
4.2	Classification .....	6
4.3	Intended clinical location .....	7
<b>5</b>	<b>Design attributes .....</b>	<b>7</b>
5.1	General .....	7
5.2	Drug-containing part of the VDDCP .....	7
5.2.1	General .....	7
5.2.2	Matrix .....	8
5.2.3	Active pharmaceutical ingredient .....	8
<b>6</b>	<b>Materials .....</b>	<b>9</b>
<b>7</b>	<b>Design evaluation .....</b>	<b>9</b>
7.1	General .....	9
7.2	Pre-clinical evaluation .....	10
7.2.1	Sampling .....	10
7.2.2	Conditioning of test samples .....	10
7.2.3	Pre-clinical in vitro test reports and additional information .....	11
7.2.4	Pre-clinical in vitro evaluation .....	11
7.2.5	Preclinical in vivo evaluation .....	17
7.3	Clinical evaluation .....	22
7.3.1	Purpose .....	22
7.3.2	Specific aims .....	22
7.3.3	Clinical investigation plan .....	22
7.3.4	Data acquisition .....	23
7.3.5	Final report .....	25
7.4	Post-market surveillance .....	26
<b>8</b>	<b>Manufacturing .....</b>	<b>26</b>
8.1	General .....	26
8.2	Raw material reporting and analysis of the API .....	26
8.3	Raw material analysis and reporting for excipients .....	27
8.4	VDDCP batch release testing .....	27
<b>9</b>	<b>Sterilization .....</b>	<b>28</b>
9.1	Products supplied sterile -- Testing to support "Sterile" labelling .....	28
9.2	Products supplied non-sterile .....	28
9.3	Sterilization residuals .....	28

<b>10</b>	<b>Packaging .....</b>	<b>28</b>
<b>10.1</b>	<b>General .....</b>	<b>28</b>
<b>10.2</b>	<b>Considerations for VDDCPs .....</b>	<b>28</b>
<b>10.3</b>	<b>Impact of changes in storage and shipping temperatures on VDDCP .....</b>	<b>28</b>
<b>11</b>	<b>Information supplied by the manufacturer .....</b>	<b>29</b>
<b>11.1</b>	<b>General .....</b>	<b>29</b>
<b>11.2</b>	<b>Labelling .....</b>	<b>29</b>
<b>11.2.1</b>	<b>VDDCP label(s) .....</b>	<b>29</b>
<b>11.2.2</b>	<b>Record label .....</b>	<b>29</b>
<b>11.3</b>	<b>Instructions for use .....</b>	<b>30</b>
	<b>Annex A (informative) Description of potential clinical and technical events .....</b>	<b>31</b>
	<b>Annex B (informative) Local information regarding submission issues for VDDCPs .....</b>	<b>36</b>
	<b>Bibliography .....</b>	<b>42</b>